News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,466 Results
Type
Article (42792)
Company Profile (280)
Press Release (682383)
Multimedia
Podcasts (77)
Webinars (19)
Section
Business (206244)
Career Advice (2156)
Deals (35705)
Drug Delivery (106)
Drug Development (81665)
Employer Resources (175)
FDA (16465)
Job Trends (15109)
News (348722)
Policy (32981)
Tag
Academia (2667)
Accelerated approval (23)
Adcomms (26)
Allergies (122)
Alliances (50181)
ALS (160)
Alzheimer's disease (1632)
Antibody-drug conjugate (ADC) (262)
Approvals (16635)
Artificial intelligence (469)
Autoimmune disease (116)
Automation (33)
Bankruptcy (364)
Best Places to Work (11722)
BIOSECURE Act (20)
Biosimilars (174)
Biotechnology (180)
Bladder cancer (144)
Brain cancer (51)
Breast cancer (589)
Cancer (4401)
Cardiovascular disease (360)
Career advice (1820)
Career pathing (35)
CAR-T (261)
CDC (45)
Celiac Disease (1)
Cell therapy (684)
Cervical cancer (35)
Clinical research (69180)
Collaboration (1478)
Company closure (4)
Compensation (1032)
Complete response letters (46)
COVID-19 (2734)
CRISPR (83)
C-suite (683)
Cystic fibrosis (135)
Data (5675)
Decentralized trials (2)
Denatured (26)
Depression (114)
Diabetes (454)
Diagnostics (6735)
Digital health (39)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (217)
Drug pricing (167)
Drug shortages (28)
Duchenne muscular dystrophy (210)
Earnings (89956)
Editorial (50)
Employer branding (22)
Employer resources (154)
Events (117501)
Executive appointments (944)
FDA (19209)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1327)
Gene editing (183)
Generative AI (40)
Gene therapy (541)
GLP-1 (923)
Government (4669)
Grass and pollen (6)
Guidances (375)
Healthcare (19036)
HIV (49)
Huntington's disease (42)
IgA nephropathy (75)
Immunology and inflammation (231)
Immuno-oncology (36)
Indications (75)
Infectious disease (2977)
Inflammatory bowel disease (178)
Inflation Reduction Act (13)
Influenza (102)
Intellectual property (210)
Interviews (342)
IPO (16667)
IRA (48)
Job creations (3734)
Job search strategy (1531)
Kidney cancer (15)
Labor market (80)
Layoffs (549)
Leadership (34)
Legal (7994)
Liver cancer (88)
Longevity (13)
Lung cancer (609)
Lymphoma (347)
Machine learning (38)
Management (60)
Manufacturing (671)
MASH (152)
Medical device (13793)
Medtech (13830)
Mergers & acquisitions (20003)
Metabolic disorders (1137)
Multiple sclerosis (143)
NASH (16)
Neurodegenerative disease (277)
Neuropsychiatric disorders (69)
Neuroscience (2725)
NextGen: Class of 2025 (6624)
Non-profit (4583)
Now hiring (60)
Obesity (529)
Opinion (262)
Ovarian cancer (150)
Pain (175)
Pancreatic cancer (189)
Parkinson's disease (253)
Partnered (31)
Patents (445)
Patient recruitment (387)
Peanut (53)
People (59043)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21559)
Phase II (30455)
Phase III (22702)
Pipeline (3767)
Policy (263)
Postmarket research (2578)
Preclinical (9239)
Press Release (68)
Prostate cancer (214)
Psychedelics (42)
Radiopharmaceuticals (263)
Rare diseases (708)
Real estate (6114)
Recruiting (70)
Regulatory (24131)
Reports (51)
Research institute (2470)
Resumes & cover letters (361)
Rett syndrome (23)
RNA editing (12)
RSV (74)
Schizophrenia (135)
Series A (214)
Series B (166)
Service/supplier (13)
Sickle cell disease (91)
Special edition (21)
Spinal muscular atrophy (154)
Sponsored (42)
Startups (3675)
State (2)
Stomach cancer (16)
Supply chain (98)
Tariffs (81)
The Weekly (49)
Vaccines (950)
Venture capital (74)
Weight loss (342)
Women's health (74)
Worklife (18)
Date
Today (116)
Last 7 days (576)
Last 30 days (2399)
Last 365 days (30447)
2025 (29727)
2024 (35447)
2023 (40337)
2022 (51497)
2021 (56038)
2020 (54545)
2019 (47112)
2018 (35444)
2017 (32555)
2016 (32008)
2015 (37989)
2014 (31718)
2013 (26835)
2012 (29042)
2011 (29708)
2010 (27656)
Location
Africa (766)
Alabama (77)
Alaska (7)
Arizona (291)
Arkansas (13)
Asia (39535)
Australia (6448)
California (10405)
Canada (3094)
China (973)
Colorado (434)
Connecticut (448)
Delaware (307)
Europe (85365)
Florida (1537)
Georgia (336)
Hawaii (2)
Idaho (62)
Illinois (781)
India (54)
Indiana (491)
Iowa (21)
Japan (361)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1312)
Massachusetts (7516)
Michigan (300)
Minnesota (584)
Mississippi (5)
Missouri (120)
Montana (30)
Nebraska (26)
Nevada (113)
New Hampshire (75)
New Jersey (2806)
New Mexico (29)
New York (2782)
North Carolina (1358)
North Dakota (9)
Northern California (4979)
Ohio (314)
Oklahoma (20)
Oregon (38)
Pennsylvania (2125)
Puerto Rico (19)
Rhode Island (45)
South America (1132)
South Carolina (58)
South Dakota (1)
Southern California (4032)
Tennessee (162)
Texas (1601)
United States (37212)
Utah (311)
Vermont (1)
Virginia (239)
Washington D.C. (78)
Washington State (855)
West Virginia (4)
Wisconsin (91)
Wyoming (2)
725,466 Results for "akili interactive labs inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
Press Releases
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19
November 19, 2025
·
1 min read
Press Releases
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 15, 2025
December 16, 2025
·
1 min read
Drug Development
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
February 27, 2024
·
10 min read
Press Releases
Virtual Therapeutics Announces Results of Tender Offer to Acquire Akili Interactive
July 2, 2024
·
6 min read
Business
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
Akili, Inc., a leading digital medicine company, reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress.
May 14, 2024
·
13 min read
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Press Releases
EVQLV Launches Abtique, the First Marketplace for AI-Designed Molecules Validated in Independent Labs
New “click-to-sequence” platform lets researchers buy AI-designed antibody sequences online, using an AI system that learns from real lab results
November 20, 2025
·
1 min read
Genetown
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD).
June 18, 2024
·
11 min read
Press Releases
BioCytics Successfully Completes a Key Regulatory Milestone with Recent FDA INTERACT Meeting
November 19, 2025
·
2 min read
1 of 72,547
Next
